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Abstract
Introduction: Endothelial progenitor cells (EPCs) play a critical role in restoration of ischemic diseases. However,
the actual status of EPC development and the mechanisms of EPC dysfunctions in patients with various ischemic
diseases remain unknown.
Methods: To investigate the detailed function of EPCs in experimental murine models, we have established an EPC
colony forming assay (EPC-CFA) in murine EPCs. The abilities of murine EPCs in differentiation, adhesive capacity,
proliferative potency, and transplantation in vitro and in vivo were then examined.
Results: Peripheral blood mononuclear cells (PB-MNCs), bone marrow mononuclear cells (BM-MNCs) or bone
marrow c-Kit+/Sca-1+ lineage negative (BM-KSL) cells differentiated into two types of EPC colony forming units
(EPC-CFUs), large sized EPC (large-EPC)-CFUs and small sized EPC (small-EPC)-CFUs. Gene expression analysis
demonstrated that both EPC-CFU-derived cells expressed eNOS, Flk-1 and VE-cadherin, markers of endothelial cells
(ECs), although the small-EPCs derived from small-EPC-CFU were higher in number and showed more immature
features (higher population of KSL cells). Functionally, the large-EPCs derived from large-EPC-CFU had higher
adhesive capacity but lower proliferative potency than small-EPCs, showing improved tubular forming capacity and
incorporation potency into primary EC-derived tube formation. Importantly, hindlimb ischemia increased the
frequencies of large-EPC-CFUs differentiated from PB-MNCs and bone marrow. Actually, transplantation of large-
EPCs into ischemic hindlimb enhanced neovascularization in hindlimb ischemia model, although small-EPCs or
murine ECs did not, suggesting that large-EPC-CFUs might play an important role in restoration of ischemic
diseases.
Conclusions: We demonstrated, using a murine ischemia model, that the EPC-CFA could be a useful way to
investigate the differentiation levels of murine EPCs, further providing a crucial clue that large-EPC-CFU status may
be more functional or effective EPCs to promote neovascularization.
Introduction
Endothelial progenitor cells (EPCs) [1-3] play an impor-
tant role in the restoration of ischemic vascular diseases
[2-5]. Recently, several independent groups have shown
that transplantation of EPCs into ischemic hindlimb or
myocardial tissue improves organ function following the
growth of new vessels [6-11]. In clinical aspects, the fre-
quency of circulating EPCs may also serve as a biomarker
for vascular function, and the number of circulating EPCs
has been reported to be reduced in patients with diabetes
mellitus or risk factors for coronary artery disease and to
negatively correlate with the Framingham cardiovascular
risk score [12-15]. However, the actual mechanical status
of EPC development and the ‘evaluation system’ for EPC
* Correspondence: asa777@is.icc.u-tokai.ac.jp
† Contributed equally
1Department Regenerative Medicine, Tokai University of Medicine,
Kanagawa, 259-1193, Japan
Full list of author information is available at the end of the article
Tsukada et al. Stem Cell Research & Therapy 2013, 4:20
http://stemcellres.com/content/4/1/20
© 2013 Tsukada et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
dysfunctions in patients with various ischemic diseases
remain to be disclosed.
Because EPCs accumulate in ischemic injured tissues
and repair injured tissue following cluster formation
[1,2,9], not only the number of EPCs identified by
uptake of acetylated-low density lipoprotein (acLDL)
and lectin reactivity but also the colony-forming poten-
tial of EPCs is important for angiogenic therapy. Thus,
the assay system in which colony-forming potential of
EPCs can be assessed is important. EPCs should encom-
pass a group of cells existing in a variety of stages, ran-
ging from hemangioblastic hematopoietic stem cells to
fully differentiated endothelial cells (ECs), and EPCs can
be classified into stages according to differentiation
levels in each circulating EPC and tissue EPC [16].
Recently, the methods to culture colony-forming unit-
endothelial cells (CFU-ECs) [14] or to culture endothe-
lial colony-forming cells (ECFCs) were established on
mononuclear cells from peripheral blood or cord blood
[17-20]. However, it was reported that CFU-ECs were
not EPCs but were myeloid cells that differentiate into
phagocytic macrophages and that T cells could mimic
the morphology of CFU-ECs [19,21]. Besides, the culture
of ECFCs enables us to evaluate the EPC colony-form-
ing potential change as EPCs differentiated during cul-
ture in vitro. In these assay systems, each EPC at
different differentiation levels could not be discriminated
at the same time, and the differentiation capacities of
immature stem cells could not be tested. In our labora-
tory, EPC-CFA, a novel method to assess the colony-
forming potential of EPCs at different differentiation
levels, was recently established and enables us to investi-
gate the commitment of each cell [22-24].
In the present study, we aimed to methodologically
establish the murine EPC-CFA on PB-MNCs, BM-MNCs,
or BM-KSL cells by analyzing the functions of each EPC-
CFU at different differentiation levels and to clarify the
roles of each EPC-CFU at different differentiation levels in
vivo by using hindlimb ischemic mice. By EPC-CFA, we
investigated the status of EPC differentiation in response
to ischemic signals and the effects of two types of EPC-
CFUs - small-EPC-CFUs or large-EPC-CFUs - in a hin-
dlimb ischemia model on in vivo neovascularization.
Materials and methods
Animals
Experiments were performed on male 8- to 10-week-old
C57BL/6J mice and BALB/CA-nu/nu mice (Japan Clea,
Tokyo, Japan) maintained under a 12-hour light/dark
cycle and in accordance with the regulations of Tokai
University. Standard laboratory chow and water were
available ad libitum. The protocols were approved by
guidelines of the Institutional Animal Care and Use
Committee of the Isehara Campus, Tokai University
School of Medicine, based on the Guide for the Care and
Use of Laboratory Animals (National Research Council)
(Institutional Review Board ID number 083005).
Preparation
Peripheral blood was obtained from the heart immediately
before sacrifice and was separated by Histopaque-1083
(Sigma-Aldrich, St. Louis, MO, USA) density gradient cen-
trifugation, as previously described [25]. Briefly, low-density
mononuclear cells were harvested and washed twice with
Dulbecco’s phosphate-buffered saline (PBS) supplemented
with 2 mmol/L ethylenediaminetetraacetic acid (EDTA).
Contaminated red blood cells were hemolyzed by using
ammonium chloride solution. BM-MNCs were obtained
by flushing the femurs and tibias and reacted with a mix-
ture of biotinylated monoclonal antibodies against B220
(RA3-6B2), CD3 (145-2C11), CD11b (M1/70), TER-119
(Ly-76), and Gr-1 (RB6-8C5) (all from BD Pharmingen,
San Diego, CA, USA) as lineage markers to deplete line-
age-positive cells from BM-MNCs by using AutoMACS
(Becton Dickinson, Franklin Lakes, NJ, USA). Lineage-
negative bone marrow cells (BM-LNneg) were incubated
with saturating concentrations of directly labeled anti-c-Kit
(at 1:25 dilution) (BD Biosciences, Franklin Lakes, NJ,
USA) and anti-Sca-1 antibodies (at 1:25 dilution) (BD Bios-
ciences) for 30 minutes on ice, and then the c-Kit+/Sca-1+
lineage-negative cells (BM-KSL) were isolated with live
sterile cell sorting (FACSVantage SE; Becton Dickinson).
Endothelial progenitor cell colony-forming assay
Various cells were cultured in methylcellulose-containing
medium M3236 (StemCell Technologies, Vancouver, BC,
Canada) with 20 ng/mL stem cell-derived factor (Kirin,
Tokyo, Japan), 50 ng/mL vascular endothelial (VE)
growth factor (R&D Systems, Minneapolis, MN, USA),
20 ng/mL interleukin-3 (Kirin), 50 ng/mL basic fibroblast
growth factor (Wako, Osaka, Japan), 50 ng/mL epidermal
growth factor receptor (Wako), 50 ng/mL insulin-like
growth factor-1 (Wako), 2 U/mL heparin (Ajinomoto,
Tokyo, Japan), and 10% fetal bovine serum (FBS) on a
35-mm dish for 8 days. Cell densities for each sample
were as follows: PB-MNCs 7 × 105 cells per dish, BM-
MNCs 1 × 104 cells per dish, BM-LNneg 2.5 × 103 cells
per dish, and BM-KSL 500 cells per dish. The EPC-CFUs
were identified as large-EPC-CFUs or small-EPC-CFUs
by visual inspection with an inverted microscope under
40× magnification. Large-EPC-CFUs were composed of
spindle-shaped cells, and small-EPC-CFUs were com-
posed of round adhesive cells.
Endothelial progenitor cell-colony-forming unit staining
After 8 days in culture, the EPC-CFU cultures were
treated with 0.4 μg/mL 1,1’-dioctadecyl-3,3,3’,3-tetra-
methyl-indocarbocyanine perchlorate-labeled acLDL
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(acLDL-DiI; Biomedical Technologies Inc., Stoughton,
MA, USA) for 1 hour and fixed by application of 1 mL
of 2% paraformaldehyde (PFA) for 1 hour at room tem-
perature. After a wash of the methylcellulose-containing
medium with PBS, the cultures were reacted with fluor-
escein isothiocyanate (FITC)-conjugated BS-1 lectin
(Sigma-Aldrich) for 1 hour at room temperature. After a
wash with PBS, the cultures were observed under a
fluorescence microscope (IX70; Olympus, Tokyo, Japan).
Large-endothelial progenitor cell or small-endothelial
progenitor cell isolation
Cells composed of small-EPC-CFUs were collected with a
pipette under a microscope as small-EPCs. Then the cul-
tures were washed with PBS, and large-EPCs were har-
vested after treatment with 2 mmol/L EDTA/PBS. For the
purpose of cell transplantation into a hindlimb ischemia
model, non-attached cells were isolated as small-EPCs by
washing with PBS, whereas attached cells were harvested
as large-EPCs by treatment with EDTA/PBS (5 mmol/L)
for 5 minutes at 37°C.
Adhesive assay
Culture plates (24-well) were coated with human fibro-
nectin (100 μg/mL; Gibco, now part of Invitrogen Cor-
poration, Carlsbad, CA, USA). Large-EPCs or small-EPCs
(2 × 104 cells per well) were allowed to attach in EGM-2
(Cambrex Bio Science Walkersville, Walkersville, MD,
USA) for 20 minutes at 37°C, and the non-adherent cells
were aspirated. The adherent population was fixed with
1% PFA for 20 minutes and stored in PBS. The numbers
of adherent cells were quantified from counts in six ran-
dom microscopic fields per well.
Proliferation assay
At day 7, EPC-CFU cultures were treated with 10 μmol/L
bromodeoxyuridine (BrdU) (Sigma-Aldrich) and incu-
bated for 24 hours. BrdU positivities of large-EPCs or
small-EPCs were analyzed by using BrdU flow kits (BD
Pharmingen) and a fluorescence-activated cell sorter, as
previously described [26].
Tubular formation assay
Two-week derived CD133- mononuclear cells of human
cord blood were used as ECs. These cells were confirmed
to be ECs by tubular formation and immunocytochemis-
try of endothelial nitric oxide synthase (eNOS), kinase
insert domain receptor (KDR), and VE-cadherin (data
not shown) [5]. Each small-EPC or large EPC was labeled
with acLDL-DiI for 1 hour. After washing of the labeled
small-EPCs or large-EPCs with PBS, the 1 × 103 cells
were mixed together with 1.2 × 104 ECs in 50 μL of 2%
FBS/EBM-2. Cell suspension (50 μL) was applied onto
50 μL of Matrigel (BD, Franklin Lakes, NJ, USA) per well
of a 96-well plate (BD Falcon, Franklin Lakes, NJ, USA)
and then incubated for 8 hours. After incubation, the
numbers of tubular formation were counted on a display
of Photoshop software (Adobe, San Jose, CA, USA) after
a picture per well was taken at 40× magnification under a
light microscope (Eclipse TE300; Nikon, Tokyo, Japan).
The numbers of incorporated labeled cells into tubes
were also counted on a display of Photoshop software
after a picture per well was taken at 100× magnification
under a fluorescence microscope.
Secondary culture
Isolated small-EPCs (5 × 104) were suspended in 50 μL
of Iscove’s modified Dulbecco’s medium (IMDM)
(Gibco) and applied onto 100 μL of methylcellulose-con-
taining medium per well of a 96-well plate (BD Falcon).
After 2 days of incubation, methylcellulose-containing
medium was changed to IMDM containing acLDL-DiI
and BS-1 lectin-conjugated FITC and then incubated for
1 hour. After a wash with PBS, cultures were observed
under a fluorescence microscope.
Reverse transcription-polymerase chain reaction
Total RNA of small-EPCs or large-EPCs was prepared
with an RNeasy Micro/Mini kit (Qiagen, Valencia, CA,
USA). Reverse transcription-polymerase chain reaction
(RT-PCR) was performed by using Superscript III Reverse
Transcriptase (Invitrogen Corporation) with 1 μg of total
RNA. PCR amplification was then performed with syn-
thetic gene-specific primers for eNOS (forward primer,
5’-GGATTGTGTCACTTCGTTCGGT-3’; reverse primer,
5’-CAGCAGGATGCCCTAACTACCA-3’; product length,
183 base pairs (bp)), Flk-1 (forward primer, 5’-AAAGAG
AGGAACGTCGGCAGA-3’; reverse primer, 5’-AAGC
ACACAGGCAGAAACCAGT-3’; product length, 376 bp),
VE-cadherin (forward primer, 5’-AGATTCACGAGC
AGTTGGTCA-3’; reverse primer, 5’-GATGTCAG AGTC
GGAGGAATT-3’; product length, 355 bp), and b-actin
(forward primer, 5’-AACACCCCAGCCATGTACGTA-3’;
reverse primer, 5’-AAGGAAGGCTGGAAAAGA GCC-3’;
product length, 416 bp) by using exTaq polymerase
(Takara, Kyoto, Japan). To quantify transcripts, semi-
quantitative RT-PCRs were performed and normalized to
Actb, which encodes b-actin. PCRs were performed at
94°C for 45 seconds, 64°C for 1 minute, and 72°C for
1 minute for 35 or 33 or 22 cycles and analyzed on 2%
agarose gels.
Flow cytometry
For flow cytometry analysis, we used monoclonal anti-
bodies specific to Sca-1 and c-Kit. BM-LNneg- or EPC-
CFU-derived cells were incubated with directly labeled
anti-Sca-1 (at 1:100 dilution) and anti-c-Kit (at 1:100
dilution) antibodies for 30 minutes on ice. The cells
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were analyzed by two-color flow cytometry by using a
FACS caliber (Becton Dickinson).
Animal model of ischemic hindlimb
Unilateral hindlimb ischemia was created in C57BL/6J
mice or BALB/CA-nu/nu as previously described [27].
Briefly, the animals were anesthetized with Nembutal (60
mg/kg intraperitoneally; Dainippon Sumitomo Pharma Co.,
Osaka, Japan) and then an incision in the skin overlying the
middle portion of the left hindlimb was performed. After
ligation of the proximal end of the femoral artery, the distal
portion of the saphenous artery was ligated and the artery,
as well as all side branches, was dissected free and excised.
The skin was closed by using a surgical stapler.
Monitoring of hindlimb blood flow
After anesthesia, hindlimb perfusion was measured by
using a laser Doppler perfusion imaging system (LDPI;
Moor Instruments, Wilmington, DE, USA). The stored
perfusion values behind the color-coded pixels represent-
ing the microvascular blood flow distribution are avail-
able for analysis. Color photographs were recorded and
analysis performed by calculating the average perfusion
of the ischemic and non-ischemic foot. To account for
variables such as ambient light and temperature, the
results are expressed as the ratio of perfusion in the left
(ischemic) versus right (normal) limb. In the EPC trans-
plantation experiment, isolated small-EPCs, large-EPCs,
or murine ECs (2.5 × 105) derived from the aorta of
C57BL/6J were transplanted into hindlimb induced nude
mice by intramuscular injection, respectively (n = 8).
Measuring of capillary density
Twenty-eight days after ischemia, capillary density was
determined in tissue sections from the lower calf muscles
of ischemic and healthy limbs by expressed as number of
CD31+ cells as ECs per myocyte. To stain the capillary,
we performed a staining procedure with rat anti-mouse
CD31 antibodies (BD Biosciences) or Alexa-fluor 594
(Molecular Probes, now part of Invitrogen Corporation)
anti-iso-lectin B4 reagents (Sigma-Aldrich).
Statistical analysis
All data were presented as mean ± standard deviation.
P values were calculated by using the unpaired Student t
test. For the analysis of in vivo ischemia experiments, the
Scheffe’s test was performed for the multiple comparisons
after analysis of variance between each group. A P value of
less than 0.05 was considered statistically significant.
Results
Development of murine endothelial progenitor cell
colony-forming assay
To address the detail functions and actual status of in
vivo EPCs, we have first established a novel EPC-CFA in
murine EPCs. After culture of PB-MNCs, BM-MNCs, or
BM-KSL of C57BL/6J mice in growth factor-containing
methylcellulose medium, these primitive cells differen-
tiated into two types of EPC colony clusters: large-EPC-
CFUs and small-EPC-CFUs (Figure 1a, data not shown).
Morphologically, these cells are large-EPC-CFUs, which
were composed mainly of spindle/round-shaped cells,
whereas cells composed of small-EPC-CFUs were round.
Both EPC-CFUs differentiated from primary PB-MNCs
or primary BM-derived cells were identified as EPCs by
acLDL uptake and BS-1 lectin reactivity, a typical fea-
ture of characterization of endothelial lineage cells (Fig-
ure 1b-d, data not shown). The frequencies of large-
EPC-CFUs or small-EPC-CFUs differentiated from 7 ×
105 PB-MNCs were 2.8 ± 1.3 and 6.0 ± 2.0 per dish,
respectively. The normalized frequencies of large-EPC-
CFUs or small-EPC-CFUs differentiated from 7 × 105
BM-MNCs were 665 ± 309 and 852 ± 82 per dish,
respectively (Figure 1e). These results revealed that
BM-MNCs had higher EPC colony-forming capacity
than PB-MNCs. In this EPC-CFA, EPCs from primary
murine cells could be classified into two types of EPC-
CFUs and the colony-forming potential could be
assessed by the frequency of EPC-CFUs. To check the
commitment of each EPC-CFU-derived cell, eNOS,
Flk-1, and VE-cadherin, markers of ECs, were examined.
Gene expression profiles revealed that large-EPCs and
small-EPCs expressed eNOS, Flk-1, and VE-cadherin
gene in both PB-MNCs and BM-MNCs (Figure 1f),
showing that large-EPCs strongly expressed VE-cad-
herin, a typical EC marker, although small-EPCs also
expressed eNOS or Flk-1, each of which is a committed
marker of endothelial lineage cells.
Characterization of large endothelial progenitor cells or
small endothelial progenitor cells
To characterize these two types of EPC-CFUs (large-
EPC-CFUs or small-EPC-CFUs), we separately collected
EPC-CFU-derived cells and investigated the functions of
both EPC-CFUs. To determine the proliferation potency
of each EPC-CFU-derived cell, we performed a prolifera-
tion assay. In PB-MNCs-derived EPC-CFUs, 24.5% ±
15.6% of large-EPCs and 51.2% ± 8.8% of small-EPCs
incorporated BrdU. In BM-MNCs-derived EPC-CFUs,
17.1% ± 13.9% of large-EPCs and 46.4% ± 23.0% of
small-EPCs incorporated BrdU (Figure 2a). More small-
EPCs incorporated BrdU than large-EPCs, suggesting
that large-EPCs have lower proliferation potency than
small-EPCs. From observation of EPC-CFUs under a
microscope, small-EPC-CFUs were constituted of more
cells than large-EPC-CFUs and the areas of small-EPC-
CFUs were significantly larger than those of large-EPC-
CFUs (data not shown). We next defined an adhesive
capacity of these two types of EPC-CFUs. The numbers
of adherent large-EPCs or small-EPCs from PB-MNCs
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were 40.5 ± 7.6 and 26.3 ± 5.6 per field, respectively, and
those from BM-MNCs were 63.7 ± 12.0 and 27.2 ± 8.0 per
field, respectively (Figure 2b), proving that the large-EPCs
have higher adhesive capacity than small-EPCs by 1.5-fold
in PB-MNCs and 2.3-fold in BM-MNCs. To check tube-
forming ability, large-EPCs or small-EPCs derived from
BM were labeled with acLDL-DiI and cocultured with ECs,
which were 2-week derived CD133- mononuclear cells of
human cord blood, on Matrigel. Fluorescent tagging of
each EPC-CFU-derived cell with DiI enabled delineation
from ECs (Figure 2c). The number of tubes in coculture
with large-EPCs increased significantly compared with
small-EPCs (large-EPCs; 78.3 ± 5.8, small-EPCs; 70.7 ± 8.4)
(Figure 2d, left). Moreover, more large-EPCs were incorpo-
rated into tubes compared with small-EPCs (large-EPCs;
8.3 ± 2.7, small-EPCs; 4.2 ± 1.7) (Figure 2d, right), implying
that large-EPCs made a substantial contribution to tubular
networks with ECs, although small-EPCs showed minimal
incorporation into the developing vascular network. Taken
together, three independent results strongly indicated that
large-EPCs and small-EPCs had different functions and
that large-EPCs might be more mature EPCs with respect
to adhesion ability and functional contribution of tubule
networks of ECs.
Importance of small-endothelial progenitor cells as large-
endothelial progenitor cell-colony-forming unit sprouting
cells
To determine whether small-EPCs are real immature
cells, we performed FACS analysis on EPC-CFU-derived
cells, which developed from fresh isolated BM-KSL (c-Kit




















































Figure 1 Murine endothelial progenitor cell colony-forming units (EPC-CFUs). (a) Representative micrographs of large-EPC-CFUs or small-
EPC-CFUs cultured from bone marrow mononuclear cells (BM-MNCs) for 8 days. Large-EPC-CFUs and small-EPC-CFUs were defined according to
cell morphology as spindle-shaped cells or round cells, respectively. (b-d) EPC-CFUs were identified as double-positive cells due to 1,1’-
dioctadecyl-3,3,3’,3-tetramethyl-indocarbocyanine perchlorate-labeled acetylated-low density lipoprotein (acLDL-DiI) uptake (red) and BS-1 lectin
reactivity (green). Scale bar represents 100 μm. (e) EPC colony-forming assay in murine peripheral blood mononuclear cells (PB-MNCs) or BM-
MNCs. The frequencies of large-EPC-CFUs (white columns) or small-EPC-CFUs (black columns) from PB-MNCs or BM-MNCs (7 × 105 cells) were
counted after 8 days of culture. *P < 0.05, **P < 0.01 versus PB-MNC-derived EPC-CFUs. (f) Expression patterns of endothelial nitric oxide
synthase (eNOS), Flk-1, and vascular endothelial (VE)-cadherin genes in large-EPCs (L) or small-EPCs (S) from PB-MNCs or BM-MNCs. Both EPC-
CFU-derived cells expressed markers of endothelial cells.
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As shown in Figure 3a, we observed the higher popula-
tion of KSL cells in small-EPCs, providing us a clue that
small-EPCs contained actual progenitors. Therefore, to
check whether small-EPCs can differentiate into large-
EPCs, isolated small-EPCs were reseeded in methylcellu-
lose-containing medium. PB-MNC-, BM-MNC-, or BM-
KSL cell-derived-small-EPCs could differentiate into
spindle-shaped cells, large-EPCs and could represent
positivity of acLDL uptake and BS-1 lectin binding (Fig-
ure 3b, data not shown). To characterize small-EPCs-
derived large-EPCs, we examined the gene expression of
VE-cadherin, Flk-1, and eNOS; adhesion capacity; and
incorporation potential of small-EPC-derived large-EPCs
(large EPCs-1) compared with small-EPCs and large-
EPCs (large EPCs-2). Gene expression profiles by RT-
PCR revealed that large EPCs-1 strongly expressed VE-
cadherin and Flk-1 compared with small-EPCs (Figure
3c). In the adhesion assay, the numbers of adherent
small-EPCs, large EPCs-1, and large EPCs-2 were 23.2 ±
5.1, 52 ± 5.3, and 61.5 ± 8.3 per field, respectively (Figure
3d). In the tubular formation assay, more large EPCs-1
were incorporated into tubes compared with small-EPCs
(Figure 3e). These results revealed that the large-EPCs
derived from small-EPCs showed a higher potential of
VE-cadherin expression, adhesion, and tube formation
compared with those of small-EPCs, suggesting that
small-EPCs might be more immature EPCs and be early
EPCs, which could differentiate into large-EPCs.
Kinetics of endothelial progenitor cell-colony-forming
units in response to ischemia
EPCs play a critical role in restoration of ischemic diseases.
To explore the effects of hindlimb ischemia on differentia-
tion of BM into EPC-CFUs, we examined PB-MNCs and
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Figure 2 Characterization of large-EPCs or small-EPCs. (a) Proliferation assay of large-EPCs or small-EPCs from peripheral blood mononuclear
cells (PB-MNCs) (upper) or bone marrow mononuclear cells (BM-MNCs) (bottom). After 7 days of culture, large-EPC-CFUs or small-EPC-CFUs were
allowed to incorporate bromodeoxyuridine (BrdU) for 24 hours and analyzed by flow cytometry. Large-EPCs had significantly lower proliferative
potency than small-EPCs in both PB-MNCs and BM-MNCs (*P < 0.05 versus large-EPCs). (b) Adhesion assay of large-EPCs or small-EPCs from PB-
MNCs or BM-MNCs. Large-EPCs (white columns) or small-EPCs (black columns) were allowed to adhere to a fibronectin-coated plate for 20
minutes. More large-EPCs had adhesive capacity than small-EPCs. *P < 0.05, **P < 0.01 versus small-EPCs. (c) Tubular formation assay of large-
EPCs or small-EPCs from BM-MNCs. Large-EPCs or small-EPCs labeled with 1,1’-dioctadecyl-3,3,3’,3-tetramethyl-indocarbocyanine perchlorate-
labeled acetylated-low density lipoprotein (acLDL-DiI) (red) were cocultured with endothelial cells (ECs) to form tubular structures within Matrigel.
Representative light and fluorescent micrographs of ECs cocultured with large-EPCs (upper) and small-EPCs (bottom) are shown. Scale bar
represents 500 μm. (d) Quantification of the number of tubes (left). Large-EPCs made a substantial contribution to tubular networks with ECs. *P
< 0.05 versus small-EPCs. (d) Quantification of the number of cells incorporated into tubes (right). Small-EPCs showed minimal incorporation into
the developing vascular network. **P < 0.01 versus small-EPCs. EPC, endothelial progenitor cell.
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BM of hindlimb ischemic mice in EPC-CFA. This experi-
ment could enable us to elucidate the roles of each EPC-
CFU in vivo. First, hindlimb perfusion was evaluated by
serial LDPI studies at day 5 after surgery. The ratio of
blood flow between the ischemic and the normal limb was
0.19 ± 0.16, which was a significant difference compared
with 0.98 ± 0.21 in the normal mice (data not shown). To
explore the in vivo change in BM, we estimated the per-
centage of KSL population in BM by FACS analysis. The
percentage of BM-LNneg did not change, but that of the
KSL population in BM-LNneg was 6.6% ± 2.0% in
ischemic mice, which was significantly increased com-
pared with the normal mice: 3.8% ± 1.2% (Figure 4a,
b). These data demonstrated that BM-KSL cells, which
produced more EPC-CFUs, were induced by hindlimb
ischemia. To check the differentiation capacities of
EPCs from PB-MNCs and various fractions of BM-
MNCs, the frequencies of EPC-CFUs from each popu-
lation were counted. In all populations, the frequencies









































































Figure 3 Importance of small-EPCs as large-EPC-CFU-sprouting cells. (a) Flow cytometry analysis of small-EPCs or large-EPCs after culturing
for 10 days from freshly isolated bone marrow c-Kit+/Sca-1+ lineage-negative cells (BM-KSL). (b) Secondary culture assay of small-EPC-CFUs from
bone marrow mononuclear cells (BM-MNCs). Representative micrographs of small-EPC-CFUs from BM-MNCs before reseeding are shown on the
left, and representative light and fluorescent micrographs of small-EPCs cultured secondarily in methylcellulose-containing medium are shown
on the right. Secondary cultured cells were identified as double-positive cells due to 1,1’-dioctadecyl-3,3,3’,3-tetramethyl-indocarbocyanine
perchlorate-labeled acetylated-low density lipoprotein (acLDL-DiI) uptake (red) and BS-1 lectin reactivity (green). Small-EPCs could differentiate
into large-EPCs. (c) The expression of vascular endothelial (VE)-cadherin, Flk-1, and endothelial nitric oxide synthase (eNOS) was measured in
small-EPCs, small-EPCs-derived large-EPCs (Large EPCs-1), and large-EPCs (Large EPCs-2) by reverse transcription-polymerase chain reaction
analysis. (d) Adhesion assay of small-EPCs, Large EPCs-1, and Large EPCs-2. *P < 0.05, **P < 0.01 versus small-EPCs. (e) Quantification of the
number of cells incorporated into tubes in small-EPCs, Large EPCs-1, and Large EPCs-2. *P < 0.05, **P < 0.01 versus small-EPCs.
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were significantly increased in hindlimb ischemic mice
(Figure 4c). These results indicated that hindlimb
ischemia induced the differentiation of PB-MNCs and
various populations of BM, implying that large-EPC-
CFUs might play an important role in the restoration
of ischemic diseases.
Contribution of large-endothelial progenitor cells or
small-endothelial progenitor cells to postnatal/adult
neovascularization
To determine the functional importance of in vivo EPC
status in a pathological situation, we transplanted large-
EPCs or small-EPCs and murine ECs as controls into hin-
dlimb ischemia models. As shown in Figure 5a, b, we
observed limb salvage in large-EPC transplantation groups,
although small-EPC, EC, or PBS transplantation groups
did not operate as useful limb therapy cells. These macro-
scopical observations were further supported by monitor-
ing of real blood flow by using a laser Doppler perfusion
imaging system because the recovery of limb perfusion
was significantly improved in large-EPCs transplantation
groups only (Figure 5c) compared with those of small-
EPC, EC, or PBS transplantation groups. Moreover, immu-
nohistochemical analysis clearly showed that capillary den-
sity in large-EPC transplantation groups was markedly
increased (Figure 5d, e), suggesting that large-EPC-CFUs
are more functional EPC status for vascular regeneration
in vivo.
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Figure 4 Development of two types of endothelial progenitor cell colony-forming units (EPC-CFUs) in response to ischemia.
(a) Fluorescence-activated cell sorting (FACS) profiles of lineage-negative bone marrow cells (BM-LNneg). FACS analysis of BM-LNneg was
performed by using rat IgG antibodies against mouse c-Kit and Sca-1. (b) The percentage of c-Kit+/Sca-1+ lineage negative (KSL) population of
BM-LNneg. Hindlimb ischemia induced KSL population in bone marrow. *P < 0.05 versus normal mice. (c) The frequencies of large-EPC-CFUs
(white columns) and small-EPC-CFUs (black columns) from peripheral blood mononuclear cells (PB-MNCs), bone marrow mononuclear cells (BM-
MNCs), BM-LNneg, and BM-KSL in normal mice (N) and hindlimb ischemic mice (I). Hindlimb ischemia increased the number of large-EPC-CFUs
and total EPC-CFUs differentiated from PB-MNCs and bone marrow. *P < 0.05, **P < 0.01 versus total EPC-CFUs from normal mice. #P < 0.05,
##P < 0.01 versus large-EPC-CFUs from normal mice. Hindlimb ischemia induced the differentiation of PB-MNCs and bone marrow.
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Discussion
EPCs can be classified into various differentiation levels in
both circulating EPCs and tissue EPCs [16]. Here, we first
defined in vivo EPC status by establishing the novel murine
EPC-CFA, in which the colony-forming potential of EPCs
at different differentiation levels can be assessed. We
demonstrated, for the first time, that hindlimb ischemia
induced onsets of large-EPCs, which might be the acceler-
ated differential status of EPCs. The observation was
further supported by an in vivo experiment in which trans-
plantation of more mature large-EPCs into a hindlimb
ischemia model enhanced neovascularization, implying the
contribution of large-EPC-CFUs in a pathogenic situation
as ‘cells ready to operate’.
Previously, Hur and colleagues [20] reported that they
found two types of EPCs - early EPCs and late EPCs -
from a source of adult PB-MNCs; attached cells that
appeared after 3 to 5 days of culture were defined as early
EPCs, and cells that appeared in 2 to 4 weeks after plating
were defined as late EPCs [20]. However, these classifica-
tions gave us some limitation for a full understanding of
the EPC status. First, as these two types of EPCs were
defined by different assays, two types of EPCs could not be
assayed synchronously. Second, these assays failed to pro-
vide enough information about the differential cascade
from immature stem cells, such as BM-KSL, into real EPC
status. In our study, we redefined EPC status in response











































































Figure 5 Effect of two types of endothelial progenitor cell colony-forming units (EPC-CFUs) on neovascularization. (a) Macroscopical
observation of ischemic hindlimb 28 days after transplantation of large-EPCs and small-EPCs, which are derived from bone marrow c-Kit+/Sca-1+
lineage-negative (BM-KSL) cells, and murine endothelial cells (mECs) into hindlimb ischemia. (b) The ratios of the above outcomes in each group. (c)
Laser Doppler perfusion imaging showing reduction of blood flow at day 28 after surgery. Quantification data of blood flow as the ratio of perfusion in
ischemic hindlimb to that in normal hindlimb are shown. In hindlimb ischemic mice, blood flow of hindlimb kept to be low in small-EPCs transplanted
and other control groups at day 28 after surgery. Transplantation of large-EPCs recovered the limb perfusion in hindlimb ischemic mice. **P < 0.01
versus mice transplanted with large-EPCs (n = 8). (d) Representative images of iso-lectin B4-positive tissue 28 days after transplantation of large-EPCs,
small-EPCs, and mECs into hindlimb ischemia. (e) The statistical data of (a). Transplantation of large-EPC-CFUs into hindlimb ischemia model enhanced
neovascularization. ***P < 0.001 versus mice transplanted with large-EPCs (n = 8). HPF, high-powered field; PBS, phosphate-buffered saline.
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proliferative activity, suggesting that small-EPC-CFUs con-
tained more immature clonogenic cells (KSL cells) derived
from hematopoietic stem cells which preserve hemagio-
blastic potentials. Large-EPC-CFUs are sequentially differ-
entiated from small-EPC-CFUs in response to ischemic
signals (Figure 6). That is, small-EPC-CFUs are ‘primitive
EPCs’ and large-EPC-CFUs are ‘definitive EPCs’. Impor-
tantly, in regard to the vasculogenic potential in vivo, our
study clearly demonstrated that transplantation of defini-
tive EPCs (large-EPCs), not primitive EPCs (small-EPCs),
markedly increased limb perfusion and capillary density
and that small-EPC-CFUs have pro-vasculogenic potential
and large-EPC-CFUs have vasculogenic potential, although
early and late EPCs were reported to contribute equally to
neovasculogenesis in a previous study [20]. Regarding the
fact that small-EPCs did not show any therapeutic effect
in Figure 5, we speculated three possibilities due to the
low adhesion and incorporation potentials of small-EPCs:
(a) transplanted small-EPCs could not survive in a hypoxic
tissue environment, (b) transplanted small-EPCs could not
differentiate into large-EPCs in a hypoxic tissue environ-
ment, and (c) transplanted small-EPCs could not show
their function as secretion of growth factors in a hypoxic
tissue environment.
Two types of EPC-CFUs represented distinct functional
differences in both in vitro EPC colony study and in vivo
EPC transplantation study. The adhesive potential and the
incorporation into tubes formed by EC-like cells of large-
EPCs were superior to those of small-EPCs, and small-
EPCs had higher proliferation capacity than large-EPCs,
which was consistent with the data on EPC-CFUs from
BM-LNneg and BM-KSL (data not shown). In these
points, definitive large-EPCs had similar functions to ECs
compared with primitive small-EPCs. Besides, the second-
ary culture revealed that small-EPCs could differentiate
into adherent cell, large-EPCs; in contrast, large-EPCs
could not differentiate into round cell, small-EPCs (data
not shown). These data showed that definitive large-EPCs
are well-differentiated EPCs compared with primitive
small-EPCs (Figure 1e). VE-cadherin is specifically
expressed in adherent junctions of ECs and exerts impor-
tant functions in cell-cell adhesion [28]. The different
expression level of VE-cadherin between large-EPCs and
small-EPCs might explain the better potential of adhesion,
incorporation into tubes, and migration (data not shown)
of definitive large-EPCs than those of primitive small-
EPCs, which were consistent with our recent findings
using human cord blood AC133+ cells [29]. Gene expres-
sion profiles revealed that both EPC-CFUs were com-
mitted to endothelial lineage because both definitive large-
EPCs and primitive small-EPCs expressed eNOS, Flk-1,
and VE-cadherin, which are EC-specific markers [5]. How-
ever, both EPC-CFUs would be different from mature ECs
in terms of colony formation capacity, tubular formation
ability, and contribution of in vivo neovascularization,
demonstrated by ischemia model, because ECs could not
form colonies and did not have an effect on the restoration
of blood vessels, and EPC-CFU-derived cells could not
form tubes on Matrigel in a culture without ECs.
In this EPC-CFA, to compare the potentials to produce
EPC-CFUs of three populations in BM (BM-MNCs, BM-
LNneg, and BM-KSL), we calculated the numbers of cells
producing one EPC-CFU in BM-MNC, BM-LNneg, and
BM-KSL populations. It was revealed that one large-EPC-
CFU was derived from 1.1 × 103 ± 0.2 × 103 BM-MNCs or
3.6 × 102 ± 1.1 × 102 BM-LNneg or 57 ± 34 BM-KSL
(Figure 1b). One small-EPC-CFU was derived from 5.5 ×
102 ± 0.7 × 102 BM-MNCs or 1.2 × 102 ± 0.2 × 102 BM-
LNneg or 28 ± 3 BM-KSL (Figure 1b). These data demon-
strated that BM-LNneg had 3- or 4.6-fold higher potential
to produce large- or small-EPC-CFUs than BM-MNCs,
respectively, and this suggested that more immature EPCs
were contained mainly in the BM-LNneg population. In
addition, it was demonstrated that BM-KSL had the high-
est potential to produce EPC-CFUs in any other popula-
tions in BM, and those potentials to produce large- or
small-EPC-CFUs were 6.3- or 4.3-fold higher than BM-
LNneg, respectively, and this suggested that immature
EPCs were highly enriched in the BM-KSL population. In
this study, using EPC-CFA, we determined that BM-KSL
was the major population which highly enriched immature
EPCs. We concluded, in this paper, that small-EPCs differ-
entiated into large-EPCs because BM-KSL grew into small-
EPCs about 5 days after plating and then those small-EPCs
derived from BM-KSL could differentiate into large-EPCs
in further culture. In our study, it remained unclear which
niche component does small- or large-EPC differentiate
from’. This should be definitely addressed in further issues.
In a clinical setting, the frequency of circulating EPCs
serves as a biomarker for vascular function, and the num-
ber of circulating EPCs has been reported to be reduced in
patients with diabetes mellitus or risk factors for coronary
artery disease and to negatively correlate with the Fra-
mingham cardiovascular risk score [12-15]. Transplanta-
tion of EPCs into ischemic hindlimb or myocardial tissue
improves organ function following new vessel growth
[6-10]. Thus, EPCs play an important role in the restora-
tion of ischemic vascular diseases. But essential molecular
events that control the differentiation to EPCs and
changes in EPCs in response to ischemia had not been
clarified yet. Then we investigated the changes of EPCs in
response to hindlimb ischemia in EPC-CFA and revealed
that the population of KSL, which enriched immature EPC
populations in BM, increased by ischemia. In previous stu-
dies, it was demonstrated that BM-derived EPCs were
mobilized in response to tissue ischemia [26]. In this
study, we showed, for the first time, that the ischemic sig-
nals could promote the differentiation of PB-MNCs,
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BM-MNCs, or BM-KSL cells into mature EPC-CFUs. Ische-
mia-induced differentiation into large-EPC-CFUs suggested
that definitive large-EPC-CFUs as more mature EPCs might
play an important role in the restoration of ischemic tissue,
and this possibility was supported by the recovery of limb
perfusion by transplantation of BM-KSL-derived large-EPCs
into a hindlimb ischemia model compared with small-EPCs.
In ischemic tissue, the expression of stromal cell-derived
factor-1 (SDF-1) was induced by transcription factor
hypoxia-inducible factor-1 (HIF-1) according to hypoxic
gradients [27,28]. SDF-1 enhances differentiation of BM-
derived c-Kit+ stem cells into EPCs [29]. Thus, the EPC dif-
ferentiation presented above might be promoted by SDF-1,
which is induced by HIF-1 after ischemia.
Conclusions
Our novel findings highlighted the actual status of EPCs














Figure 6 Schematic model of endothelial progenitor cell (EPC) development. In an endothelial progenitor cell colony-forming assay
(EPC-CFA), three different stages of EPC development were classified: (1) stem cell stage as EPC-sprouting cells, (2) early stage of EPCs as large-
EPC-CFU-sprouting cells, which contained mostly immature small cells, and (3) late stage of EPCs as functional EPCs, which contained mostly big
spindle cells. EPC-CFU, endothelial progenitor cell colony-forming unit. EC, endothelial cell; KSL, c-Kit+/Sca-1+ lineage-negative.
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through BM-derived stem cells using our established
murine EPC-CFA. The understanding of molecular cas-
cades of EPC development from primitive small-EPC-
CFUs to definitive large-EPC-CFUs will provide us some
useful therapeutic advantages to solve the quantitative
or qualitative problems for EPCs therapy.
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